3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Arthritis, Rheumatoid
12
Spondylitis, Ankylosing
4
Psoriasis
2
Inflammatory Bowel Diseases
2
Thyroid Carcinoma, Anaplastic
1
Spondylarthritis
1
Sarcoidosis
1
Osteoarthritis
1
Nephrotic Syndrome
1
Nephrosis, Lipoid
1
Mucopolysaccharidosis VI
1
Mucopolysaccharidosis II
1
Mucopolysaccharidosis I
1
Mucopolysaccharidoses
1
Macular dystrophy, corneal type 1
1
Kidney Diseases
1
Joint Diseases
1
Inflammation
1
Infections
1
Glomerulosclerosis, Focal Segmental
1
Dupuytren Contracture
1
Crohn Disease
1
Colitis, Ulcerative
1
Autoimmune Diseases
1
Arthritis, Psoriatic
1
Arthritis
1
Interventions
trametinib
8
dabrafenib
7
pembrolizumab
5
Paclitaxel
5
lenvatinib
4
Radiotherapy, Intensity-Modulated
3
Doxorubicin
3
fosbretabulin
2
cobimetinib
2
cemiplimab
2
atezolizumab
2
Vemurafenib
2
Sorafenib
2
Nivolumab
2
Bevacizumab
2
zimberelimab
1
tremelimumab
1
selpercatinib
1
sapanisertib
1
sacituzumab govitecan
1
pegfilgrastim
1
fludarabine
1
efatutazone
1
durvalumab
1
ceritinib
1
cabozantinib
1
aldesleukin
1
abemaciclib
1
Thyroidectomy
1
Taxes
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Thyroid Carcinoma, Anaplastic
×
Adalimumab
×
Clear all
NCT02516774
2016-01-26
TAM-RT
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1
Withdrawn